Physician profile
Shahram Javaheri
NPI 1497861439
$7,210.58
in general payments reported to CMS, 2019-2025
35 companies · $750 in 2025
The $750 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,135 · 2020: $852 · 2021: $1,440 · 2022: $1,382 · 2023: $736 · 2024: $916 · 2025: $750.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,402.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,402.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,116.01 | 2019-2025 | Stelara, Tremfya, Simponi |
| Abbvie INC. | $1,115.20 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,020.26 | 2019-2025 | Xifaxan, Plenvu, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $538.18 | 2019-2024 | Gattex, Entyvio |
| Genzyme Corporation | $357.61 | 2022-2025 | |
| Nestle Healthcare Nutrition INC. | $263.19 | 2021-2023 | |
| Allergan, INC. | $246.02 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $241.86 | 2021-2022 | |
| Braintree Laboratories, INC. | $190.61 | 2019-2025 | Suflave, Sutab |
| Ironwood Pharmaceuticals, INC | $170.69 | 2020-2022 | |
| Intercept Pharmaceuticals, INC. | $151.33 | 2019-2022 | |
| Celgene Corporation | $147.84 | 2022-2023 | Zeposia |
| Regeneron Healthcare Solutions, INC. | $144.81 | 2022-2024 | Dupixent |
| Pfizer INC. | $132.73 | 2019-2025 | |
| Ferring Pharmaceuticals INC. | $126.15 | 2021-2023 | Rebyota |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $122.75 | 2025 | Rezdiffra |
| Intra-Sana Laboratories | $120.08 | 2021 | |
| Qol Medical, LLC | $115.44 | 2019-2022 | |
| Alfasigma USA, INC. | $111.40 | 2020-2021 | |
| Daiichi Sankyo INC. | $76.30 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $76.10 | 2019-2020 | |
| Gilead Sciences, INC. | $67.77 | 2019-2025 | |
| Lilly USA, LLC | $67.59 | 2024-2025 | Omvoh |
| Celltrion USA INC. | $67.43 | 2024-2025 | Vegzelma, Zymfentra |
| Redhill Biopharma INC. | $67.00 | 2021-2022 | |
| Aimmune Therapeutics, INC. | $62.40 | 2024 | |
| Ardelyx, INC. | $49.05 | 2025 | Ibsrela |
| Ionis Pharmaceuticals, INC. | $46.39 | 2025 | Tryngolza |
| Boston Scientific Corporation | $45.21 | 2024 | Autocap Rx, Exalt Model D |
| Endogastric Solutions, INC | $37.05 | 2019-2023 | Esophyx |
| Vivus LLC | $35.14 | 2019-2021 | |
| Shire North American Group INC | $24.54 | 2019 | |
| Pacira Pharmaceuticals Incorporated | $21.06 | 2022 | |
| Erbe USA INC | $18.00 | 2025 | Vio3 |
| Phathom Pharmaceuticals, INC. | $17.39 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shahram Javaheri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.